Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Experience
100%
Single Institution
100%
MiR-223
100%
External Beam Radiotherapy
71%
Alkaline Phosphatase
57%
Bone Marrow Failure
57%
Pain Score
57%
Eastern Cooperative Oncology Group
57%
Abiraterone
57%
Group Status
57%
Event-free Survival
42%
Hemoglobin
28%
Chemotherapy
28%
Overall Survival
28%
Hazard Ratio
28%
Progression-free Survival
28%
Beneficial Effects
14%
Serum Levels
14%
Outcome Prediction
14%
Prostate-specific Antigen
14%
Multivariable
14%
Risk of Progression
14%
Concomitant Use
14%
Baseline Features
14%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
14%
PSA Doubling Time
14%
Prostate-specific Antigen Doubling Time
14%
Radium
14%
Overall Survival Progression-free Survival
14%
Enzalutamide
14%
Score Use
14%
Medicine and Dentistry
External Beam Radiotherapy
100%
Oncology
80%
Alkaline Phosphatase
80%
Bone Marrow Failure
80%
Abiraterone
80%
Overall Survival
60%
Event Free Survival
60%
Progression Free Survival
60%
Prostate Specific Antigen
40%
Hazard Ratio
40%
Castration Resistant Prostate Cancer
20%
Enzalutamide
20%
Pharmacology, Toxicology and Pharmaceutical Science
Alkaline Phosphatase
100%
Bone Marrow Depression
100%
Abiraterone
100%
Overall Survival
75%
Progression Free Survival
75%
Event Free Survival
75%
Chemotherapy
50%
Prostate Specific Antigen
50%
Castration Resistant Prostate Cancer
25%
Enzalutamide
25%
Nursing and Health Professions
External Beam Radiotherapy
100%
Alkaline Phosphatase
80%
Bone Marrow Depression
80%
Abiraterone
80%
Overall Survival
60%
Event Free Survival
60%
Progression Free Survival
60%
Prostate Specific Antigen
40%
Hazard Ratio
40%
Blood Level
20%
Castration Resistant Prostate Cancer
20%
Enzalutamide
20%
Immunology and Microbiology
Radiation Beam
100%
Phosphatase
80%
Overall Survival
60%
Progression Free Survival
60%
Event Free Survival
60%
Prostate Specific Antigen
40%
Hemoglobin
40%
Blood Level
20%
Prostate
20%